Credit: Celltrion CRS is a life-threatening condition that results in the excessive release of cytokines into the bloodstream, causing inflammation and damage to organs and tissues. With the newly ...

The transition from preclinical development to clinical trials is a critical, yet high-risk stage in drug development, with approximately 89% of drugs failing to progress through all phases of ...

Please provide your email address to receive an email when new articles are posted on . Treatment with siltuximab following CAR-T reduced severity of CRS and ICANS. A phase 2 prospective study is ...

Beyond Efficacy: Cost and Resource Implications of First-Line Systemic Therapies for Metastatic Renal Cell Carcinoma Talquetamab is a G protein–coupled receptor class C group 5 member D ...

Autoimmune diseases result from a complex interaction of immune system imbalances, marked by a breakdown in self-tolerance and sustained inflammation. At the core of this dysregulation are ...

Under normal conditions, cytokines aid in pathogen recognition and elimination while contributing to immune system homeostasis. When the immune system malfunctions, irregularities in cytokine ...

With the newly approved indication for CRS, Avtozma IV now aligns with all approved indications for Actemra IV. CRS is a life-threatening condition in which an overactive immune response leads to the ...